GATE-101 not checked

Syndeio Biosciences, Inc

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“GATE-101 is a metabotropic glutamate receptor type 2/3 antagonist”In the company’s words, NCT04618263 on ClinicalTrials.gov
Tested for
Major Depressive Disorder, Excessive Sleepiness
Main trialPhase 1
“To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers”In the company’s words, NCT04618263 on ClinicalTrials.gov

Other drugs for Major Depressive Disorder

All 36 drugs for Major Depressive Disorder

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Terminated 13 Aug 2021 Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow GATE-101

Following is part of Solo: you see every change to GATE-101 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in